−1.48USD
−59.69 MUSD
1.00 MUSD
51.45 M
About Milestone Pharmaceuticals Inc.
Sector
CEO
Joseph G. Oliveto
Headquarters
Montréal
Website
Employees (FY)
47
Founded
2003
ISIN
CA59935V1076
FIGI
BBG009DR4MN8
Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. Its lead product candidate etripamil, is a novel, potent and short-acting calcium channel blocker that is designed as a rapid-onset nasal spray to be self-administered by patients. It develops etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, rapid ventricular rate, and other cardiovascular indications. The company was founded by Philippe Douville and Philippe Lamarre in 2003 and is headquartered in Montreal, Canada.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of MIST is 1.63 USD — it has decreased by 6.86% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Milestone Pharmaceuticals Inc. stocks are traded under the ticker MIST.
Milestone Pharmaceuticals Inc. is going to release the next earnings report on May 15, 2024. Keep track of upcoming events with our Earnings Calendar.
MIST stock is 12.80% volatile and has beta coefficient of 0.94. Check out the list of the most volatile stocks — is Milestone Pharmaceuticals Inc. there?
One year price forecast for Milestone Pharmaceuticals Inc. has a max estimate of 25.00 USD and a min estimate of 3.00 USD.
MIST earnings for the last quarter are −0.35 USD whereas the estimation was −0.38 USD which accounts for 8.38% surprise. Estimated earnings for the next quarter are −0.31 USD. See more details about Milestone Pharmaceuticals Inc. earnings.
Milestone Pharmaceuticals Inc. revenue for the last quarter amounts to 1.50 M USD despite the estimated figure of 0 USD. In the next quarter revenue is expected to reach 1.17 M USD.
Yes, you can track Milestone Pharmaceuticals Inc. financials in yearly and quarterly reports right on TradingView.
MIST stock has fallen by 4.12% compared to the previous week, the month change is a 7.24% rise, over the last year Milestone Pharmaceuticals Inc. has showed a 57.77% decrease.
MIST net income for the last quarter is −13.61 M USD, while the quarter before that showed −15.08 M USD of net income which accounts for 9.75% change. Track more Milestone Pharmaceuticals Inc. financial stats to get the full picture.
Today Milestone Pharmaceuticals Inc. has the market capitalization of 93.01 M, it has increased by 1.11% over the last week.
No, MIST doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, MIST shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Milestone Pharmaceuticals Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 47.00 employees. See our rating of the largest employees — is Milestone Pharmaceuticals Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Milestone Pharmaceuticals Inc. technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Milestone Pharmaceuticals Inc. stock shows the sell signal. See more of Milestone Pharmaceuticals Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Milestone Pharmaceuticals Inc. future price: according to them, MIST price has a max estimate of 25.00 USD and a min estimate of 3.00 USD. Read a more detailed Milestone Pharmaceuticals Inc. forecast: see what analysts think of Milestone Pharmaceuticals Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Milestone Pharmaceuticals Inc. EBITDA is −60.81 M USD, and current EBITDA margin is −6.08 K%. See more stats in Milestone Pharmaceuticals Inc. financial statements.